Furthermore, we performed a phase II clinical trial of the same vaccine for HLA-A*24:02-positive patients with recurrent glioblastoma multiforme (GBM) and again showed that it was safe with more favorable clinical outcomes than obtained with previously reported approaches for recurrent GBM [21]. Here, HLA-A is linked to glioblastoma.